Fuso Pharmaceutical Industries,Ltd.

Tokyo Stock Exchange 4538.T

Fuso Pharmaceutical Industries,Ltd. Receivables for the year ending March 31, 2024: USD 160.74 M

Fuso Pharmaceutical Industries,Ltd. Receivables is USD 160.74 M for the year ending March 31, 2024, a -1.78% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Fuso Pharmaceutical Industries,Ltd. Receivables for the year ending March 31, 2023 was USD 163.64 M, a -5.82% change year over year.
Fuso Pharmaceutical Industries,Ltd. Receivables for the year ending March 31, 2022 was USD 173.76 M, a -10.01% change year over year.
Fuso Pharmaceutical Industries,Ltd. Receivables for the year ending March 31, 2021 was USD 193.10 M, a 1.79% change year over year.
Fuso Pharmaceutical Industries,Ltd. Receivables for the year ending March 31, 2020 was USD 189.71 M, a -4.66% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Tokyo Stock Exchange: 4538.T

Fuso Pharmaceutical Industries,Ltd.

CEO	Mr. Mikio Toda
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	1-7-10, Doshomachi
Employees	1,370
Sector	Consumers Staples
Industries Cleaning Supplies Automotive Parts Composite Materials Hardware & Electronics Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics

Description

Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.

Key trends

Past 5 years